• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Catherine Shaffer

Catherine Shaffer

Articles

ARTICLES

Agenus Is Hit Hard by GSK Trial Failure

Sep. 6, 2013
By Catherine Shaffer
Shares of Agenus Inc., of Lexington, Mass., plummeted 23.5 percent on news that Glaxosmithkline plc’s Phase III DERMA trial testing its MAGE-A3 cancer immunotherapeutic, formulated with Agenus’s QS-21 Stimulon adjuvant, missed its primary endpoint. The trial failed to significantly extend disease-free survival in melanoma patients compared to placebo.
Read More

New Hedge Fund Has Roots in Dendreon

Sep. 5, 2013
By Catherine Shaffer
Former Dendreon Corp. CEO Mitch Gold and investment analyst David Miller have teamed up to open a new Seattle-based hedge fund, Alpine BioVentures. The multimillion-dollar fund will invest in newer companies in the biotech space, particularly in the area of cancer and rare diseases.
Read More

Syria Crisis to Delay Action on Health Spending

Sep. 4, 2013
By Catherine Shaffer
It will be anything but business as usual when Congress reconvenes on Sept. 9, as the debate on military action in Syria is expected to compress the congressional schedule prior to Oct. 1, leading to uncertainty about budget sequestration, funding for health care and research spending.
Read More

Neurotrope Reverse Merger Raises $21M

Sep. 3, 2013
By Catherine Shaffer
Neurotrope Inc. completed a reverse merger making Neurotrope Bioscience Inc. – a wholly owned subsidiary – in hopes of bolstering fundraising efforts to advance its programs in Alzheimer’s disease.
Read More

Positive Phase II Results Boost Astex Shares

Aug. 29, 2013
By Catherine Shaffer
Shares of Astex Pharmaceuticals Inc. surged 24 percent Wednesday on top-line results from the company’s Phase II trial of cancer candidate SGI-110 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Read More

Sangamo Adds Gene Therapy Assets with Ceregene Buyout

Aug. 28, 2013
By Catherine Shaffer
Sangamo BioSciences Inc., of Richmond, Calif., will acquire a Phase II Alzheimer’s disease gene therapy, CERE-110, plus a device for brain delivery with its acquisition of San Diego-based Ceregene Inc. Sangamo agreed to hand over 100,000 shares of its common stock, plus a payout on revenues from its products.
Read More

Basilea Stock Takes a Hit on FDA Guidelines for Antibiotic Trials

Aug. 23, 2013
By Catherine Shaffer
The FDA has maintained a firm stance on clinical trial requirements for Basilea Pharmaceutica Ltd.'s broad-spectrum antibiotic ceftobiprole for skin infections. In its half-year financial update, Basilea indicated that the agency would require two pivotal trials per indication. Basilea's stock (SW:BSLN) closed Thursday at CHF70.75 (US$76.67), down CHF2.45.
Read More

Patent Dustup Threatens Cozy Collaborations

Aug. 22, 2013
By Catherine Shaffer
When what was once an open and collegial research relationship erupted into a patent inventorship lawsuit between the University of Utah and the University of Massachusetts, researchers Brenda Bass and Thomas Tuschl, once colleagues in a closely related field, became parties in the suit.
Read More

Adimab Signs Two New Antibody Deals

Aug. 21, 2013
By Catherine Shaffer
Adimab LLC, of Lebanon, N.H., announced two new collaborations centered on its platform for generating therapeutic antibodies.
Read More

Pain Therapeutics, Durect Still 'Not Out of the Woods'

Aug. 20, 2013
By Catherine Shaffer
Pain Therapeutics Inc. and Durect Corp. each enjoyed a stock surge when news got out that Pfizer Inc. began a new clinical trial of Remoxy (oxycodone) three months after the pharma had signaled that it was considering discontinuation of the product.
Read More
View All Articles by Catherine Shaffer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe